Latest & greatest articles for clindamycin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on clindamycin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on clindamycin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for clindamycin

1. Early clindamycin for bacterial vaginosis in pregnancy (PREMEVA): a multicentre, double-blind, randomised controlled trial. (PubMed)

Early clindamycin for bacterial vaginosis in pregnancy (PREMEVA): a multicentre, double-blind, randomised controlled trial. Preterm delivery during pregnancy (<37 weeks' gestation) is a leading cause of perinatal mortality and morbidity. Treating bacterial vaginosis during pregnancy can reduce poor outcomes, such as preterm birth. We aimed to investigate whether treatment of bacterial vaginosis decreases late miscarriages or spontaneous very preterm birth.PREMEVA was a double-blind randomised (...) controlled trial done in 40 French centres. Women aged 18 years or older with bacterial vaginosis and low-risk pregnancy were eligible for inclusion and were randomly assigned (2:1) to three parallel groups: single-course or triple-course 300 mg clindamycin twice-daily for 4 days, or placebo. Women with high-risk pregnancy outcomes were eligible for inclusion in a high-risk subtrial and were randomly assigned (1:1) to either single-course or triple-course clindamycin. The primary outcome was a composite

2018 Lancet

2. Clindamycin to reduce preterm birth in a low resource setting: a randomised placebo-controlled clinical trial

Clindamycin to reduce preterm birth in a low resource setting: a randomised placebo-controlled clinical trial To determine whether oral clindamycin reduces the risk of preterm birth (PTB) in women with abnormal vaginal microflora as evidenced by a vaginal pH ≥5.0.Randomised double-blind placebo-controlled trial.Rural southern India.Pregnant women with a singleton fetus between 13+0/7 weeks and 20+6/7 weeks.Pregnant women were recruited during prenatal visits in Karnataka, India, from October (...) 2013 to July 2015. Women were required to have a singleton fetus between 13+0/7 weeks and 20+6/7 weeks and an elevated vaginal pH (≥5.0) by colorimetric assessment. Participants were randomised to either oral clindamycin 300 mg twice daily for 5 days or an identical-appearing placebo.The primary outcome was the incidence of PTB, defined as delivery before 37+0/7 weeks.Of the 6476 screened women, 1727 women were randomised (block randomised in groups of six; clindamycin n = 866, placebo n = 861

2018 EvidenceUpdates

3. Clindamycin

Clindamycin Top results for clindamycin - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for clindamycin The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence

2018 Trip Latest and Greatest

4. Clindamycin versus trimethoprim-sulfamethoxazole for uncomplicated skin infections. (PubMed)

Clindamycin versus trimethoprim-sulfamethoxazole for uncomplicated skin infections. Skin and skin-structure infections are common in ambulatory settings. However, the efficacy of various antibiotic regimens in the era of community-acquired methicillin-resistant Staphylococcus aureus (MRSA) is unclear.We enrolled outpatients with uncomplicated skin infections who had cellulitis, abscesses larger than 5 cm in diameter (smaller for younger children), or both. Patients were enrolled at four study (...) sites. All abscesses underwent incision and drainage. Patients were randomly assigned in a 1:1 ratio to receive either clindamycin or trimethoprim-sulfamethoxazole (TMP-SMX) for 10 days. Patients and investigators were unaware of the treatment assignments and microbiologic test results. The primary outcome was clinical cure 7 to 10 days after the end of treatment.A total of 524 patients were enrolled (264 in the clindamycin group and 260 in the TMP-SMX group), including 155 children (29.6%). One

Full Text available with Trip Pro

2015 NEJM

5. Clindamycin Exhibits No Statistical Difference in Preoperative Compared to Postoperative Administration For The Prevention of Dry Socket

Clindamycin Exhibits No Statistical Difference in Preoperative Compared to Postoperative Administration For The Prevention of Dry Socket UTCAT2622, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Clindamycin Exhibits No Statistical Difference in Preoperative Compared to Postoperative Administration For The Prevention of Dry Socket Clinical Question For dry socket prevention is it more efficacious to administer (...) clindamycin pre-surgery compared to post-surgery? Clinical Bottom Line Clindamycin is effective in preventing dry socket occurrence following tooth extraction, but there is no significant difference in preoperative versus postoperative administration. This is supported by a retrospective study in which postoperative clindamycin administration significantly decreased the incidence of dry socket. A randomized clinical trial (RCT) demonstrated clindamycin was equally efficacious, and showed no statistical

2014 UTHSCSA Dental School CAT Library

6. There Is No Difference In The Rates Of Third Molar Post-Operative Inflammatory Complications Between Patients With 600mg Clindamycin, and Patients Without Antibiotics

There Is No Difference In The Rates Of Third Molar Post-Operative Inflammatory Complications Between Patients With 600mg Clindamycin, and Patients Without Antibiotics UTCAT2447, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title There Is No Difference In The Rates Of Third Molar Post-Operative Inflammatory Complications Between Patients With 600mg Clindamycin, and Patients Without Antibiotics Clinical Question (...) In a patient undergoing a third molar extraction, will a clindamycin prophylaxis prevent postoperative inflammatory complications compared to no postoperative antibiotics? Clinical Bottom Line There is no difference in the rates of third molar post-operative inflammatory complications between patients with clindamycin, and patients without antibiotics. For immunocompetent patients undergoing third molar extractions, there is no apparent reason to provide any clindamycin antibiotic intervention

2013 UTHSCSA Dental School CAT Library

7. Effect of peritoneal lavage with clindamycin-gentamicin solution on infections after elective colorectal cancer surgery (PubMed)

Effect of peritoneal lavage with clindamycin-gentamicin solution on infections after elective colorectal cancer surgery Colorectal surgery may lead to infections because despite meticulous aseptic measures, extravasation of microorganisms from the colon lumen is unavoidable.A prospective, randomized study was performed between January 2010 and December 2010. Patient inclusion criteria were a diagnosis of colorectal neoplasms and plans to undergo an elective curative operation. Patients were (...) divided into 2 groups: Group 1 (intra-abdominal irrigation with normal saline) and Group 2 (intraperitoneal irrigation with a solution of 240 mg gentamicin and 600 mg clindamycin). The occurrence of wound infections and intra-abdominal abscesses were investigated. After the anastomosis, a microbiologic sample of the peritoneal surface was obtained (sample 1). A second sample was collected after irrigation with normal saline (sample 2). Finally, the peritoneal cavity was irrigated with a gentamicin

2012 EvidenceUpdates

8. Treatment of abnormal vaginal flora in early pregnancy with clindamycin for the prevention of spontaneous preterm birth: a systematic review and metaanalysis (PubMed)

Treatment of abnormal vaginal flora in early pregnancy with clindamycin for the prevention of spontaneous preterm birth: a systematic review and metaanalysis The purpose of this study was to determine whether the administration of clindamycin to women with abnormal vaginal flora at <22 weeks of gestation reduces the risk of preterm birth and late miscarriage. We conducted a systematic review and metaanalysis of randomized controlled trials of the early administration of clindamycin to women (...) with abnormal vaginal flora at <22 weeks of gestation. Five trials that comprised 2346 women were included. Clindamycin that was administered at <22 weeks of gestation was associated with a significantly reduced risk of preterm birth at <37 weeks of gestation and late miscarriage. There were no overall differences in the risk of preterm birth at <33 weeks of gestation, low birthweight, very low birthweight, admission to neonatal intensive care unit, stillbirth, peripartum infection, and adverse effects

Full Text available with Trip Pro

2011 EvidenceUpdates

9. Randomized controlled trial of cephalexin versus clindamycin for uncomplicated pediatric skin infections (PubMed)

Randomized controlled trial of cephalexin versus clindamycin for uncomplicated pediatric skin infections To compare clindamycin and cephalexin for treatment of uncomplicated skin and soft tissue infections (SSTIs) caused predominantly by community-associated (CA) methicillin-resistant Staphylococcus aureus (MRSA). We hypothesized that clindamycin would be superior to cephalexin (an antibiotic without MRSA activity) for treatment of these infections.Patients aged 6 months to 18 years (...) with uncomplicated SSTIs not requiring hospitalization were enrolled September 2006 through May 2009. Eligible patients were randomly assigned to 7 days of cephalexin or clindamycin; primary and secondary outcomes were clinical improvement at 48 to 72 hours and resolution at 7 days. Cultures were obtained and tested for antimicrobial susceptibilities, pulsed-field gel electrophoresis type, and Panton-Valentine leukocidin status.Of 200 enrolled patients, 69% had MRSA cultured from wounds. Most MRSA were USA300

Full Text available with Trip Pro

2011 EvidenceUpdates

10. Clindamycin phosphate 2% vaginal cream (Clindesse) for the treatment of bacterial vaginosis

Clindamycin phosphate 2% vaginal cream (Clindesse) for the treatment of bacterial vaginosis Clindamycin phosphate 2% vaginal cream (Clindesse) for the treatment of bacterial vaginosis | Therapeutics Initiative Independent Healthcare Evidence > > Clindamycin phosphate 2% vaginal cream (Clindesse) for the treatment of bacterial vaginosis Introduction Pharmaceutical Services Division (PSD) requested a systematic review of Clindesse for the treatment of non-pregnant women ≥ 18 years of age (...) with bacterial vaginosis. Drug Clindesse is a semi-solid white cream containing 2% clindamycin phosphate, which is a water-soluble ester of the semi-synthetic antibiotic produced by a 7 (S)-chloro-substitution of the 7(R)-hydroxyl group of the parent antibiotic, lincomycea. The recommended dose is a single intravaginal administration on one day. Disease Bacterial vaginosis is a common vaginal infection caused by an imbalance in the vaginal flora. In bacterial vaginosis there is suppression of lactobacilli

2010 Therapeutics Letter

11. Veltin (clindamycin phosphate and tretinoin) Gel

Veltin (clindamycin phosphate and tretinoin) Gel Drug Approval Package: Veltin (clindamycin phosphate and tretinoin) NDA #050803 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Veltin (clindamycin phosphate and tretinoin) Gel, 1.2%/0.025% Company: Stiefel, a GSK company Application No.: 050803 Approval Date: 07/16/2010 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF

2010 FDA - Drug Approval Package

12. [Treatment of pregnant women with asymptomatic bacterial vaginosis with clindamycin]

[Treatment of pregnant women with asymptomatic bacterial vaginosis with clindamycin] Klindamycin til gravide med asymptomatisk bakteriell vaginose [Treatment of pregnant women with asymptomatic bacterial vaginosis with clindamycin] Klindamycin til gravide med asymptomatisk bakteriell vaginose [Treatment of pregnant women with asymptomatic bacterial vaginosis with clindamycin] Myrhaug HT, Brurberg KG, Kirkehei I, Reinar LM Record Status This is a bibliographic record of a published health (...) technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Myrhaug HT, Brurberg KG, Kirkehei I, Reinar LM. Klindamycin til gravide med asymptomatisk bakteriell vaginose. [Treatment of pregnant women with asymptomatic bacterial vaginosis with clindamycin] Oslo: Norwegian Knowledge Centre for the Health Services (NOKC). Report from NOKC nr 11 - 2010. 2010 Authors' conclusions Clindamycin treatment of pregnant women

2010 Health Technology Assessment (HTA) Database.

13. An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once-daily treatment of moderate to severe acne vulgaris: Assessment of efficacy and safety in 2813 patients (PubMed)

An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once-daily treatment of moderate to severe acne vulgaris: Assessment of efficacy and safety in 2813 patients We sought to evaluate efficacy, safety, and tolerability of a combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% (clindamycin-BPO 2.5%) aqueous gel in moderate to severe acne vulgaris.A total of 2813 patients, aged 12 years or older, were randomized to receive clindamycin-BPO (...) with clindamycin-BPO 2.5% as early as week 2. No substantive differences were seen in cutaneous tolerability among treatment groups and less than 1% of patients discontinued treatment because of adverse events.Data from controlled studies may differ from clinical practice.Clindamycin-BPO 2.5% provides statistically significant greater efficacy than individual active ingredients and vehicle with a highly favorable safety and tolerability profile.

2008 EvidenceUpdates

14. Effect of early oral clindamycin on late miscarriage and preterm delivery in asymptomatic women with abnormal vaginal flora and bacterial vaginosis: a randomised controlled trial. (PubMed)

Effect of early oral clindamycin on late miscarriage and preterm delivery in asymptomatic women with abnormal vaginal flora and bacterial vaginosis: a randomised controlled trial. Abnormal vaginal flora and bacterial vaginosis are associated with amplified risks of late miscarriage and spontaneous preterm delivery. We aimed to establish whether antibiotic treatment early in the second trimester might reduce these risks in a general obstetric population.We screened 6120 pregnant women attending (...) hospital for their first antenatal visit--who were at 12-22 weeks' gestation (mean 15.6 weeks)--for bacterial vaginosis or abnormal vaginal flora. We used gram-stained slides of vaginal smears to diagnose abnormal vaginal flora or bacterial vaginosis, in accordance with Nugent's criteria. We randomly allocated 494 women with one of these signs to receive either clindamycin 300 mg or placebo orally twice daily for 5 days. Primary endpoints were spontaneous preterm delivery (birth > or =24 but <37 weeks

2003 Lancet

15. Clinical and economic impact of a pharmacist-intervention to promote sequential intravenous to oral clindamycin conversion

Clinical and economic impact of a pharmacist-intervention to promote sequential intravenous to oral clindamycin conversion Clinical and economic impact of a pharmacist-intervention to promote sequential intravenous to oral clindamycin conversion Clinical and economic impact of a pharmacist-intervention to promote sequential intravenous to oral clindamycin conversion Martinez M J, Freire A, Castro I, Inaraja M T, Ortega A, Del Campo V, Rodriguez I, Bardan B, Morano L E, Garcia J F Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The health technology examined in the study was a pharmacist-intervention (through an information sheet) for the promotion of sequential therapy with antibiotics (clindamycin), defined as the early change from

2000 NHS Economic Evaluation Database.

16. Tissue concentration of clindamycin and gentamicin near ischaemic ulcers with transvenous injection in Bier's arterial arrest. (PubMed)

Tissue concentration of clindamycin and gentamicin near ischaemic ulcers with transvenous injection in Bier's arterial arrest. In the treatment of patients with inflamed ischaemic ulcers in peripheral arterial occlusive disease, high tissue concentrations of antibiotics (TCA) are important. With local transvenous pressure injection in Biers' arterial arrest (TVA-Bier) higher TCAs are assumed to be obtained but they have not been measured.Two groups of 16 patients each with ischaemic foot ulcers (...) were studied. In one group, patients received a mean of 284 (SD 116) mg gentamicin and in the other, 1200 mg clindamycin. The antibiotics were given intravenously, intra-arterially, and by TVA-Bier in a randomised order at intervals of 48 hours. Biopsy samples were taken from the edge of the ulcers 20 minutes and 3 hours after TVA-Bier, and 1 hour and 3 hours after intravenous and intra-arterial injection. At the same times blood samples were taken.TCAs of gentamicin and clindamycin with TVA-Bier

1996 Lancet

17. Pharmacoeconomics of aztreonam-clindamycin versus gentamicin-clindamycin in the treatment of penetrating abdominal injury

Pharmacoeconomics of aztreonam-clindamycin versus gentamicin-clindamycin in the treatment of penetrating abdominal injury Pharmacoeconomics of aztreonam-clindamycin versus gentamicin-clindamycin in the treatment of penetrating abdominal injury Pharmacoeconomics of aztreonam-clindamycin versus gentamicin-clindamycin in the treatment of penetrating abdominal injury Fabian T C, Boucher B A, Croce M C Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Aztreonam-clindamycin (A-C) versus gentamicin-clindamycin (G-C) in the treatment of penetrating abdominal injury. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Adult patients with suspected penetrating intraabdominal injury

1996 NHS Economic Evaluation Database.

18. Meta-analysis of parenteral clindamycin dosing regimens

Meta-analysis of parenteral clindamycin dosing regimens Meta-analysis of parenteral clindamycin dosing regimens Meta-analysis of parenteral clindamycin dosing regimens Rovers J P, Ilersich A L, Einarson T R Authors' objectives To evaluate the differences in clinical outcomes for 2 different dosages of parenteral clindamycin, 600 and 900 mg, both 8 hourly, in adult patients with intra-abdominal infection or female pelvic infection. Searching MEDLINE, EMBASE and International Pharmaceutical (...) Abstracts were searched for English language articles describing clindamycin use in humans. Additional sources were personal and drug information centre files, and the reference lists of retrieved papers. Study selection Study designs of evaluations included in the review Comparative studies of both open and blind design were included. Specific interventions included in the review Parenteral dosages of clindamycin, 600 mg or 900 mg 8 hourly. Comparable treatments included any other regimen

1995 DARE.

19. Toxicity of clindamycin as prophylaxis for AIDS-associated toxoplasmic encephalitis. Community Programs for Clinical Research on AIDS. (PubMed)

Toxicity of clindamycin as prophylaxis for AIDS-associated toxoplasmic encephalitis. Community Programs for Clinical Research on AIDS. A double-blind, placebo-controlled trial was set up to compare clindamycin and pyrimethamine as prophylaxis for toxoplasmic encephalitis (TE) in HIV-infected patients at risk of the disorder. Interim analysis showed that clindamycin-treated patients were 4.4 (95% confidence interval 1.3-15.2) times more likely to experience an adverse effect that necessitated (...) withdrawal of the study drug than those who received placebo. Diarrhoea and rash were reported in 16 (31%) and 11 (21%), respectively, of 52 patients treated with clindamycin (300 mg twice daily) compared with 2 (6%; p = 0.06) and none (p = 0.01) of the 32 placebo-treated patients. The clindamycin arm of the trial was prematurely terminated, although recruitment to the pyrimethamine arm continues.

1992 Lancet

20. Prevention of recurrent staphylococcal skin infections with low-dose oral clindamycin therapy. (PubMed)

Prevention of recurrent staphylococcal skin infections with low-dose oral clindamycin therapy. We conducted a double-blind, controlled trial of low-dose (150 mg/d) oral clindamycin hydrochloride vs placebo to prevent recurrent staphylococcal skin infections. Twenty-two patients (11 in both the placebo and clindamycin treatment groups) completed the trial and were assessable. The two groups did not differ as to age, sex, race, or the number of recurrent abscesses preceding the trial. In pretrial (...) evaluations, no patient had hypogammaglobulinemia or abnormal neutrophil function. Sixty-four percent (7/11) of the placebo-treated patients had a recurrent abscess within three months of enrollment whereas 82% (9/11) of the patients treated with clindamycin were free of any infection during the three-month treatment period. Of the nine patients who responded to clindamycin treatment, six did not have a recurrent infection for at least nine months after discontinuing antibiotic therapy. All patients

1988 JAMA